Ro43 83582

structure in first source

Also Known As:

1,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)-23-yne-26,27-hexafluorocholecalciferol; 1alpha,25-dihydroxy-20S-21-(3-hydroxy-3-methylbutyl)-23-yne-26,27-hexafluorocholecalciferol; 21-(3-OH-methylbutyl)-23-yne-26,27-F6-1alpha,25(OH)2D3; Ro 438-2582; Ro-438-3582; Ro3582; Ro43-83582

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Goodman, Catherine: 1 article (07/2006)
2.	Ji, Yan: 1 article (07/2006)
3.	Lee, Hong Jin: 1 article (07/2006)
4.	Liu, Hao: 1 article (07/2006)
5.	Maehr, Hubert: 1 article (07/2006)
6.	Notterman, Daniel: 1 article (07/2006)
7.	Reiss, Michael: 1 article (07/2006)
8.	Suh, Nanjoo: 1 article (07/2006)
9.	Uskokovic, Milan: 1 article (07/2006)

Related Diseases

1.	Carcinogenesis 07/28/2006 - "The Gemini Vitamin D(3) analog Ro3582 induced more significant gene changes in the early premalignant MCF10AT1 cells than in the malignant metastatic MCF10CA1a cells, suggesting that Gemini Vitamin D(3) analogs may be more effective in preventing the progression of an early stage of breast carcinogenesis than in treating late stage breast cancer."
2.	Breast Neoplasms (Breast Cancer) 07/28/2006 - "The Gemini Vitamin D(3) analog Ro3582 induced more significant gene changes in the early premalignant MCF10AT1 cells than in the malignant metastatic MCF10CA1a cells, suggesting that Gemini Vitamin D(3) analogs may be more effective in preventing the progression of an early stage of breast carcinogenesis than in treating late stage breast cancer."

Related Drugs and Biologics

1.	Cholecalciferol (Vitamin D3)